Navigation Links
Roche Extends Tender Offer for Ventana
Date:1/16/2008

BASEL, Switzerland, Jan. 16 /PRNewswire-FirstCall/ -- Roche (OTCQX: RHHBY; SWX: ROG.VX; RO.S), a world-leading healthcare provider of pharmaceuticals and diagnostics, announced today that it has extended its offer to acquire all of the outstanding common shares of Ventana Medical Systems, Inc. (Nasdaq: VMSI) to 5:00 p.m., New York City time on Friday, March 14, 2008. The tender offer was previously scheduled to expire at 5:00 p.m., New York City time, on January 17, 2008. All other terms and conditions of the tender offer remain unchanged. As of the close of business on January 16, 2008, approximately 62,401 shares have been tendered pursuant to the offer.

Greenhill & Co. and Citi are acting as financial advisors to Roche and Davis Polk & Wardwell is acting as legal counsel.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders and diseases of the central nervous system. In 2006 sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
2. Roche Files IND for Second Genmab Antibody
3. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
4. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
5. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
6. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
7. Kosan to Reacquire Epothilone Program From Roche
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
11. Med Ad News Honors Roche as Company of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood Registry® ... of the 10th Annual World Stem Cell Summit, the largest ... The 2014 World Stem Cell Summit will be held December ... Texas . The World Stem ... of lifesaving cures and therapies, convening the most prominent figures ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... Empowers Users to Take Full Control of the ... to Results Disclosure - while Adhering to Changing ... to Manage Their Clinical Trial Registration and Results ... ( http://www.intrasphere.com ), a ...
... , - European Operating ... Healthcare Educational Program, Accepted,for Accreditation , ... healthcare barrier,protective solutions, has announced it has taken a ... the area of continued,education. , ...
... developed an entirely new method for starting chemical reactions. ... control catalytic activity one of the most fundamental ... reactions with mechanical force. This discovery paves the way ... influence of mechanical tension. The results of their research ...
Cached Biology Technology:Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4A molecular ripcord for chemical reactions 2
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... November 2014)—In support of a bold quest to rid ... Gates Foundation today announced an award of US$156 million ... (MVI) in building new vaccines that will interrupt the ... "accelerating to zero" agenda. Such vaccines would ensure that ... called an "immunological bed net." , This approach ...
(Date:11/2/2014)... walk into a bar and bump into a biologist . ... to some late-night nerd sketch, researchers have taken this premise ... biology, namely, finding meaning in the rising oceans of genomic ... cancer mutations that genome-wide studies are publishing at a dizzying ... parse the signal from the noise (and there is no ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... of some insects or the deep black of a ... the nanostructure of a fly,s eyes, according to Penn ... and inexpensively copy biological surface structures. "Only a ... says Akhlesh Lakhtakia, the Charles Godfrey Binder (Endowed) Professor ...
... size guidelines for all-terrain vehicles (ATV) are inadequate to ... results from a study by researchers at the University ... found that national ATV size guidelines for youth ... frame or engine size do not assure a ...
... of sedentary and overweight older people placed on a four-month ... more fat, compared to older sedentary people who were placed ... study also showed that when older people diet without exercising, ... said senior researcher Bret H. Goodpaster. When they combined weight ...
Cached Biology News:Coating copies microscopic biological surfaces 2Coating copies microscopic biological surfaces 3Study finds ATV guidelines inadequate 2Older people who diet without exercising lose valuable muscle mass 2
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
... Silver Staining Kit is uniquely formulated ... with minimal protein modification for optimal ... problems associated with traditional silver stains ... because the reagents used do not ...
...
Biology Products: